In 2003, Johnson & Johnson allegedly sent letters to 700,000 physicians, claiming Risperdal was the better antipsychotic drug in comparison to its competitors. The Food and Drug Administration sent the pharmaceutical company a warning letter saying it is making false and misleading claims that did not properly alert physicians about the risks of diabetes and that over-exaggerated the drug’s quality over other competitor’s medications, according to the report.
Jurors in a Louisiana state court said in the verdict that Johnson & Johnson officials defrauded the federal Medicaid program by making false claims about Risperdal. Consequently, Johnson & Johnson will pay $7,250 for each of the more than 35,000 violations of the state’s Medical Assistance Programs Integrity Law, amounting to more than $257 million, according to the report.
Read the Bloomberg Businessweek news report about Johnson & Johnson’s verdict.
Read other coverage about pharmaceutical company fraud:
– AARP to Join False Claims Lawsuit Against Pharmaceutical Companies
– CEOs of Drug Companies Guilty of Off-Label Promotion May Face Misdemeanor Prosecutions, Warns FDA
– Merck Seeks Appeal on $4.6M Verdict in Fraud Case
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
